Inclusion Criteria : 
  1.  Initiation of treatment with a single ICI or a combination of ICIs . 
  2.  Acceptation of an informed consent . 
Exclusion Criteria : 
  1.  Life expectancy lower than 3 months from the initiation of treatment with ICIs . 
  2.  Proven hypersensitivity or previous allergic anaphylactic reaction induced by a specific ICI . 
  3.  Active autoimmune disease with severe involvement . 
  4.  Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¥ 3. 
  5.  Ongoing immunosuppressive therapy : prednisone at doses > 10 mg / day or equivalent (  > 1.5 mg / day of dexamethasone )  , and / or any dose of azathioprine , methotrexate , mycophenolate , cyclophosphamide , leflunomide , rituximab , anti - tumor necrosis factor drugs ( infliximab , etanercept , adalimumab , golimumab )  , belimumab and abatacept.